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non-small-cell lung cancer (NSCLC) using geﬁ tinib or docetaxel. Probability distribu-
tions for adverse events and life expectancy were obtained from the INTEREST
study. We used a docetaxel chemotherapy cost-study at ISSSTE and for geﬁ tinib 
we used the drug’s institutional price. Health state utility values for calculating
QALYs (Quality Adjusted Life Years) were derived from a recently published study
done with UK patients. A 3% annual discount rate was applied on a monthly basis
to all costs. Finally, a probabilistic sensitivity analysis was made varying the cost of 
chemotherapy. The model was run 25 times with 500 patients in each arm. Results
are presented in US dollars with an exchange rate of 13.5 MXN pesos for 1 US dollar. 
RESULTS: There was no clinical difference in life expectancy between geﬁ tinib (10.25
months) and docetaxel (10.14 months). Average QALY for geﬁ tinib cohort was 0.487 
(95% CI, 0.437 – 0.537) and for chemotherapy cohort was 0.438 (95% CI, 0.388 –
0.488). The average cost per patient treated with geﬁ tinib was $12,103 (95% CI, 
$11,916 – $12,290) and with docetaxel was $20,076 (95% CI, $19,866 – $20,286).
The acceptability curve shows a 100% dominace of geﬁ tinib over docetaxel, after a
chemotherapy price of $1,333. CONCLUSIONS: Geﬁ tinib is an alternative therapy 
for second line treatment of NSCLC that dominates docetaxel chemotherapy, in terms 
of quality of life related to reduced presence of adverse events, at a lesser cost to the 
institution.
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OBJECTIVES: Chronic myelogenous leukaemia (CML) is a progressive disease associ-
ated with a signiﬁ cant burden on both the patient and the health care provider. 
Although durable response from imatinib is achievable for many patients, some
develop resistance or intolerance. In these patients, other tyrosine kinase inhibitors 
(TKIs), such as dasatinib and nilotinib are treatment options. This study uses outputs
from recent clinical trials evaluating TKIs to predict the long-term economic and cost 
outcomes associated with different levels of best response. METHODS: A Markov
model was developed to estimate the costs and health outcomes associated with 
chronic, accelerated and blast phase CML. Short-term response was deﬁ ned as ‘no
response’ (NR), ‘complete haematological response’ (CHR), partial cytogenetic
response (PCR) and complete cytogenetic response (CCR). Resource use and quality-
adjusted life year (QALY) scores were stratiﬁ ed according to the patient’s current 
health status and response level. RESULTS: Patients in the chronic phase who achieve 
no response are estimated to experience a total of 1.50 QALYs and incur costs of 
a57,867 over their lifetime. Those who achieve CHR, PCR and CCR experience 3.47,
7.31 and 10.17 QALYs, and costs of a62,617, a66,499 and a67,117 respectively. In
the accelerated phase, the total number of QALYs for the NR, CHR, PCR and CCR
groups were 0.71, 1.70, 1.57 and 4.10 respectively. For the same groups, the lifetime 
costs were a35,273, a35,850, a35,886 and a51,693. In the blast phase, the QALY 
outcomes for the four groups were 0.18, 0.41, 0.63 and 1.46, whilst the costs were 
a13,252, a7,109, a10,993 and a25,501 respectively. CONCLUSIONS: There is a 
strong apparent relationship between short-term response to treatment and long-
term outcomes in CML. These ﬁ ndings are likely to be useful in assessing the cost-
effectiveness of existing treatments, whose short-term response is known, but where 
long-term data are currently unavailable.
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OBJECTIVES: To estimate the cost effectiveness of Posaconazole versus ﬂ uconazole/
itraconazole therapy in the prophylaxis against invasive fungal Infections among high-
risk neutropenic patients in Mexico. METHODS: A previously validated Markov
model was used to compare the projected lifetime costs and effects of two theoretical 
groups of patients, one receiving Posaconazol and the other receiving ﬂ uconazole/itra-
conazole. The model estimates total costs, numbers of IFIs, and QALY per patient in
each prophylaxis group. The model was extended with one-month Markov cycles in
which mortality risk is speciﬁ c to the underlying disease. Data on the probabilities of 
IFI were obtained from Study Protocol PO1899. Drug costs were taken from average 
wholesale drug reports for 2008. Cost and health effects were discounted at 5%. The
analysis was conducted from the Mexican health care perspective using 2008 unit cost
prices. RESULTS: Our model projects an accumulated cost to the Mexican health care
system per patient receiving the Posaconazol regimen of US$7463 compared to 
US$5634 for the ﬂ uconazole/itraconazole regimen. This results in an incremental cost
of –(US$1829) per patient. The accumulated discounted effect is 3.13 life years or 
2.25 quality adjusted life years (QALYs) per patient receiving Posaconazol, compared 
to 3.13 life years or 2.13 QALYs per patient receiving ﬂ uconazole/itraconazol. This 
translates into an incremental effect of posaconazole over ﬂ uconazole/itraconazole of 
0.17 life years gained (LYG) or 0.12 QALYs gained. The corresponding incremental 
cost effectiveness ratio (iCERs) is -(US$15,125) per QALY. Probabilistic sensitivity 
analysis tested numerous assumptions about the model cost and efﬁ cacy parameters
and found that the results were robust to most changes. CONCLUSIONS: The use of 
temozolomide in place of ﬂ uconazole/itraconazole for the prophylaxis against invasive
fungal Infections among high-risk neutropenic patients is likely to be cost saving. 
These conclusions are supported by the use of conservative assumptions and sensitivity 
analyses.
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OBJECTIVES: Patients receiving myelosuppressive chemotherapy are at risk for che-
motherapy-induced neutropenic complications (CINC). The study objective was to
examine the impact of CINC, deﬁ ned as neutropenia with fever or infection, on short-
term disability (STD) among cancer patients receiving chemotherapy. METHODS:
Patients with cancer undergoing chemotherapy were extracted from Thomson Reuters
MarketScan Commercial Database and Health and Productivity Management Data-
base. Patients were required to have at least 6 months continuous enrollment before 
the index date (ﬁ rst chemotherapy claim) and at least 30 days continuous enrollment
post-index date, full-time employment and eligibility for STD. Patients with ICD-9
codes for neutropenia and fever or infection and that had evidence of chemotherapy 
within 30 days prior were deﬁ ned as having CINC. Propensity score (PS) matching
was conducted for “CINC” and “non-CINC” patients based on demographic and
clinical characteristics, including chemotherapy class and use of highly myelosuppres-
sive chemotherapeutic agents. Subsequent multivariate regressions were conducted on
PS-matched cohorts to estimate the marginal impact of CINC: an Ordinary Least 
Squares Model on STD days, a generalized linear model on indirect cost associated 
with STD, and a logistic regression model on whether a patient used any STD days
during a month. RESULTS: A total of 280 CINC and 280 non-CINC patients were
PS-matched. Compared with matched non-CINC patients, CINC patients on average 
experienced 0.9 more STD day (3.2 vs. 2.3, p  0.046) which led to $156 more in
indirect costs ($549 vs. $394, p  0.050) per month. After multivariate adjustment,
CINC patients were 35% (p  0.121) more likely to experience at least one STD day,
experienced 1.0 more STD day (p  0.029), and incurred $200 more in indirect cost 
(p  0.016) per month. CONCLUSIONS: Patients with CINC experience signiﬁ cantly 
greater STD days than patients with no neutropenic complications from cancer che-
motherapy. Efforts that may prevent CINC can potentially have a beneﬁ cial impact 
on work absenteeism.
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OBJECTIVES: The accident at the Chernobyl nuclear power plant in 1986 released 
an enormous amount of radioactive materials which spread over the territories of 
Ukraine, Belarus, Russia and other European countries. The damage caused to the
environment, economy and, most importantly, to human health has been challenging 
to estimate. In fact, there is no scientiﬁ c agreement on the severity of the Chernobyl
aftermath. The purpose of our paper is to investigate the long-run impact of the
tragedy on the labor market outcomes of the Ukrainian population. METHODS:
Speciﬁ cally, using data from 2001 household survey and a self-reported measure of 
well-being, we estimate the impact of the Chernobyl accident on individual earnings. 
In addition, we identify a substantial gender wage gap existing in the Ukrainian labor 
markets. We use the Oaxaca decomposition technique to examine the wage gap in 
more detail. RESULTS: We ﬁ nd that those individuals whose health has suffered as a
result of the accident receive on average 5% lower wages, after controlling for other 
characteristics. CONCLUSIONS: We ﬁ nd that a large portion of the wage gap is 
“unexplained” and may be attributed to discrimination against women; in addition,
the health effects of the Chernobyl accident explain a signiﬁ cant portion of the gender 
wage inequality.
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OBJECTIVES: After initial therapy with imatinib, chronic myelogenous leukemia 
(CML) patients who do not completely respond may require dose escalation or switch-
ing to another BCR/ABL kinase inhibitor to achieve the desired response. This study 
compared health care resource utilization associated with either escalation of imatinib 
dose or switching to dasatinib. METHODS: Two large administrative claims databases 
were combined (MarketScan and Ingenix Impact, January 1999–March 2008) to 
identify patients diagnosed with CML (ICD-9 code: 205.1). Patients initiated with 
imatinib who were continuously enrolled 6 months prior to and at least one month 
following their ﬁ rst dose increase or switch to dasatinib were selected. Patients who
switched to dasatinib before reaching imatinib 800 mg/day (switchers) and the non-
